Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment

  title={Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment},
  author={Harsh Shah and Ulka N. Vaishampayan},
  journal={Targeted Oncology},
With the decrease in PSA screening based on the 2011 United States Preventive Services Task Force guidelines and the potential approval of highly sensitive imaging techniques over the next few years, we are likely to see an increasing trend of metastatic prostate cancer diagnosis. Traditional therapy for nonmetastatic prostate cancer (nmPC) has consisted of androgen deprivation therapy (ADT) followed by other hormonal therapy maneuvers, such as anti-androgen withdrawal, herbal preparations, low… 
Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future
  • T. Gourdin
  • Medicine, Biology
    Current opinion in oncology
  • 2019
Novel radiopharmaceuticals and immunotherapies suggest progress is on the horizon for men with castration-resistant prostate cancer, and individualized therapies directed at specific genomic aberrations are providing potentially additional treatment options for patients with refractory disease.
Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.
INTRODUCTION To interpret data and update the traditional categorization of prostate cancer in order to help treating clinicians make more informed decisions. These updates include guidance regarding
Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
The prostate-specific membrane antigen (PSMA) has emerged as an attractive diagnostic and therapeutic target for small molecule ligands in prostate cancer and this review article summarizes the important concepts for Precision Medicine contributing to improved diagnosis and targeted therapy of patients with prostate cancer.
Intracrine androgen biosynthesis and drug resistance
This review focuses on intracrine androgen biosynthesis, how this can contribute to ARSI drug resistance, and therapeutic strategies that can be used to surmount these resistance mechanisms.
Hypoxia - an explanation of prostate cancer progression mechanisms
There is now a considerable amount of clinical evidence that tumors with a higher proportion of hypoxic cells have a poor diagnosis, and prostate cancer cells seem to be highly tolerant of hypoxia.
Biomarkers of Immunotherapy Response and the Future Role of Targeted Therapies in Non-metastatic Prostate Cancer
  • S. Slovin
  • Medicine
    Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
  • 2022


Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer
Abiraterone is highly effective and has an excellent safety profile for the treatment of metastatic castrate-naïve prostate cancer and should now be considered the new standard of care, according to the authors.
Darolutamide (ODM-201) for the treatment of prostate cancer
  • N. Shore
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2017
Darolutamide is an oral, investigational, high-affinity AR antagonist which has activity against known AR mutants that confer resistance to other second-generation antiandrogens, has minimal blood–brain barrier penetration, and does not significantly increase serum testosterone, which may offer potential advantages over the second- Generation antiandrogen.
Abiraterone and increased survival in metastatic prostate cancer.
The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
There is an urgent need for new agents that provide palliation and improve survival in men with metastatic prostate cancer, including chemotherapy with docetaxel for patients with CRPC.
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Detection of AR-V7 in CTCs from men with metastatic CRPC is not associated with primary resistance to taxane chemotherapy, and clinical outcomes were superior with taxanes compared with enzalutamide or abiraterone therapy in AR-v7-positive men, whereas outcomes did not differ by treatment type in AR/V7-negative men.